PitchBook-生物技术风险投资基金的演变（英）-2025_22页_1mb

PitchBook: The Evolution of Biotech VC Funds

Overview

The biotech venture capital (VC) ecosystem has undergone a complete market cycle from 2012 to 2024, marked by a boom from $12.1 billion to $152.3 billion in 2018, followed by a significant market correction returning to 2012 levels by 2024. This cycle consists of three phases: steady ascent (2012-2017), explosive expansion (2018-2021), and market rationalization (2022-2024). The correction is driven by rising cost of capital, post-pandemic market reset, exit market constraints, and sector reallocation.

Key Findings

1. Market Cycle:

   • Raising $121 billion in 2012 to a peak of $152.3 billion in 2018 before declining to $12 billion in 2024.
   • Completing a full boom-bust-reset cycle.

2. Specialist vs. Generalist Dynamics:

   • In 2012, specialists held 30% of biotech capital; generalists surged to 92% in 2018.
   • By 2024, specialists reclaimed 72% ($8.6 billion) from generalists' 28% ($3.4 billion).

3. VC Ecosystem Contraction:

   • Biotech's share of total VC funding fell from 19% in 2012 to 6% in 2024.
   • Biotech funds represent only 3% of all VC funds in 2024.

4. Performance Trends:

   • Biotech funds outperformed non-biotech funds in 2021-2023 with an IRR of 11.9% vs. 0.3%.
   • Biotech specialization creates value during market stress, reversing previous patterns.

5. Geographic Distribution:

   • North America dominates (80.5% of global biotech VC in 2024), followed by Europe (14.2%) and Asia (5.3%).
   • Key hubs include Boston, San Francisco, Basel, and Cambridge.

6. Fund Size Distribution:

   • Mega funds ($1 billion+) reduced activity since 2024; concentration shifted to funds between $250M-$500M.

7. Outlook:

   • Current recalibration establishes a potentially sustainable foundation for future innovation.
   • LPs favor experienced managers, strategic deployment, and extended value-creation timelines.
   • Emerging trends include RNA therapies, AI-driven R&D, and cross-domain technology integration.

Data Highlights

• Total Capital Raised: $152.3B peak in 2018, $12B in 2024.
• Fund Count Trend: Declined from 309 funds in 2021 to 46 funds in 2024.
• Key Players: Flagship Pioneering, ARCH Venture Partners, Roche Venture Fund, and Novo Holdings REPAIR Fund.

Performance Analysis

• Vintage Year Comparison:
  • 2021-2023: Biotech IRR 11.9%, non-biotech 0.3%.
  • 2021-2023 Top-decile TVPI: 1.6x (vs. Non-biotech 1.3x).
• Returns reflect maturation cycles, with specialist funds demonstrating resilience.

Outlook

Biotech VC funds may now stabilize funding levels, potentially paving the way for disciplined investment in niche areas like cell therapies, AI-driven biotech, and strategic corporate ventures.